Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of administration of
multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with
moderately active Ulcerative Colitis (UC) followed by a Long-term Extension Therapy (LTE)
phase for eligible subjects with a clinical response.